CRISPR-based diagnostics enable specific sensing of DNA and RNA biomarkers associated with
human diseases. This is achieved through the binding of guide RNAs to a complementary
sequence which activates Cas enzymes to cleave reporter molecules. Currently, most CRISPRbased diagnostics rely on target preamplification to reach sufficient sensitivity for clinical
applications. This limits quantification capability and adds complexity to the reaction chemistry.
Here, we show the combination of a CRISPR/Cas-based reaction with a Nanozyme-Linked
ImmunoSorbent Assay which allows for the quantitative and colorimetric readout of Cas13-
mediated RNA detection through catalytic metallic nanoparticles at room temperature
(CrisprZyme). We demonstrate CrisprZyme is easily adaptable to a lateral-flow-based readout
and different Cas enzymes, and enables the sensing of non-coding RNAs including microRNAs,
long non-coding RNAs and circular RNAs. We utilise this platform to identify patients with acute
myocardial infarction and to monitor cellular differentiation in vitro and in tissue biopsies from
prostate cancer patients. We anticipate that CrisprZyme has significant potential as a universally
applicable signal catalyst for CRISPR-based diagnostics which will expand the spectrum of
targets for preamplification-free, quantitative detection.